CENTRAL NERVOUS SYSTEM DISEASES
Clinical trials for CENTRAL NERVOUS SYSTEM DISEASES explained in plain language.
Never miss a new study
Get alerted when new CENTRAL NERVOUS SYSTEM DISEASES trials appear
Sign up with your email to follow new studies for CENTRAL NERVOUS SYSTEM DISEASES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets inflammation to slow early Alzheimer's
Disease control CompletedThis study tested an experimental drug called XPro1595 in 208 people with early Alzheimer's disease who also had signs of brain inflammation. The goal was to see if the drug could improve thinking, memory, and daily function compared to a placebo over 24 weeks. The study also che…
Matched conditions: CENTRAL NERVOUS SYSTEM DISEASES
Phase: PHASE2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Can social networks prevent second strokes? new study says maybe.
Disease control CompletedThis study tested whether using social networks (like WeChat) can help people at high risk for stroke take their medications correctly after leaving the hospital. 720 participants were split into two groups: one received standard care, the other got extra support through social n…
Matched conditions: CENTRAL NERVOUS SYSTEM DISEASES
Phase: NA • Sponsor: Changhai Hospital • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New stent retriever shows promise in clearing Stroke-Causing clots
Disease control CompletedThis study tested a new device called the Supernova stent retriever in 54 people having a severe stroke caused by a large blood clot in the brain. The device is designed to grab and remove the clot, restoring blood flow. The main goals were to see if the device could safely reope…
Matched conditions: CENTRAL NERVOUS SYSTEM DISEASES
Phase: NA • Sponsor: Gravity Medical Technology, INC • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Tiny tots, big data: gadopiclenol safety in infants
Knowledge-focused CompletedThis study looked at how the contrast agent gadopiclenol is processed in the bodies of 36 infants up to 23 months old who needed an MRI. The goal was to measure drug levels and safety, not to treat any disease. Results help doctors use the right dose for young children.
Matched conditions: CENTRAL NERVOUS SYSTEM DISEASES
Phase: PHASE2 • Sponsor: Guerbet • Aim: Knowledge-focused
Last updated May 17, 2026 03:09 UTC